These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36477110)

  • 21. [Anti-CD19 CART (C-CAR011) Therapy for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma].
    Zhang L; Zhang Y; Zhou DB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1141-1147. PubMed ID: 34362494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
    Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
    Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.
    Li J; Mu J; Wang J; Li X; Li Q; Jiang Y; Cui R; Deng Q
    Cell Transplant; 2024; 33():9636897241247951. PubMed ID: 38651796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
    J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with
    Zhang J; Cai D; Gao R; Miao Y; Cui Y; Liu Z; Zhang H; Yan X; Su N
    Front Immunol; 2023; 14():1307242. PubMed ID: 38143763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
    Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
    J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
    Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
    J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.
    Yan ZX; Dong Y; Qiao N; Zhang YL; Wu W; Zhu Y; Wang L; Cheng S; Xu PP; Zhou ZS; Sheng LS; Zhao WL
    Nat Commun; 2024 Jun; 15(1):5183. PubMed ID: 38890370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
    Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
    Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
    Front Immunol; 2022; 13():879983. PubMed ID: 35669773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
    [No Abstract]   [Full Text] [Related]  

  • 37. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of CRISPR-based non-viral
    Hu Y; Zu C; Zhang M; Wei G; Li W; Fu S; Hong R; Zhou L; Wu W; Cui J; Wang D; Du B; Liu M; Zhang J; Huang H
    EClinicalMedicine; 2023 Jun; 60():102010. PubMed ID: 37251628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Bouchkouj N; Lin X; Wang X; Przepiorka D; Xu Z; Purohit-Sheth T; Theoret M
    Oncologist; 2022 Oct; 27(10):892-899. PubMed ID: 35983953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
    Jacobson CA; Hunter BD; Redd R; Rodig SJ; Chen PH; Wright K; Lipschitz M; Ritz J; Kamihara Y; Armand P; Nikiforow S; Rogalski M; Maakaron J; Jaglowski S; Maus MV; Chen YB; Abramson JS; Kline J; Budde E; Herrera A; Mei M; Cohen JB; Smith SD; Maloney DG; Gopal AK; Frigault MJ; Acharya UH
    J Clin Oncol; 2020 Sep; 38(27):3095-3106. PubMed ID: 32667831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.